Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Ambitious Plans For Follow-On Biologics

Executive Summary

Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
Advertisement

Related Content

Merck Likes Biosimilars, But Not ESAs
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009
Big Pharma’s March Into Biotech Could Make Big Biologics A Big ’09 Theme
Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme
J&J Talks Up Wellness As Economy, Generics Shadow ’09
Merck Outlines Plans For 2009 NDA Filings; Migraine Drug Is Best Bet
Merck's Head-long Leap into Follow-On Biologics
Pharma's New Follow-On Strategy
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Advertisement
UsernamePublicRestriction

Register

PS050448

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel